Revolution Medicines (RVMD) Q2 FY26 earnings call

Revolution Medicines reported a transformational quarter, marked by the FDA's acceptance of daraxonrasib's NDA for pancreatic cancer and significant progress in its expanded access program. The company also showcased compelling clinical data for its RAS(ON) inhibitors in both pancreatic and non-small cell lung cancers, reinforcing its broad pipeline strategy. Despite increased operating expenses and net loss driven by accelerated development and commercialization efforts, the company maintains a strong financial position to advance its mission in RAS-addicted cancers.